Stockreport

A Look At ImmunityBio (IBRX) Valuation After ANKTIVA's Macau Approval And NCCN Guideline Expansion [Yahoo! Finance]

ImmunityBio, Inc.  (IBRX) 
PDF ImmunityBio (IBRX) drew investor attention after Macau regulators approved ANKTIVA for certain bladder cancer patients, and updated US NCCN guidelines widened the group [Read more]